Sami Miettinen has been appointed CEO of Abomics, bringing global health technology leadership experience to the field of pharmacogenetics. His appointment supports the company’s next phase of growth in delivering clinically integrated solutions that enable more precise, personalized medication decisions.
Abomics is pleased to announce the appointment of Sami Miettinen as Chief Executive Officer (CEO) as of May 1st, 2024, succeeding former CEO Valter Rönnholm.
Sami joins Abomics from GE Healthcare, where he served as Global Marketing Director, Anesthesia and Respiratory Care business. Prior to that, he served in several global roles withing GE HealthCare and brings expertise in global marketing, product management and R&D.
Sami commented “I am excited to join Abomics to help drive the next phase of growth for the business. Abomics has an exceptional solution and great reputation in the field of pharmacogenetics and is uniquely positioned to support doctors in medication decisions and enabling precision medication for patients. Abomics is known for its professional team, and it is an honor to lead such an accomplished group of people. ”
Jari Forsström, Chief Medical Officer at Abomics stated “We are delighted to welcome Sami Miettinen as the new Chief Executive Officer at Abomics. Joining us from GE HealthCare, Sami brings a wealth of experience and leadership that will be invaluable as we accelerate growth and deliver long-term value for our expanding customer base across the pharmacogenomics field.
I would also like to take this opportunity to thank Valter Rönnholm for his leadership of Abomics which saw the organization achieve solid progress during challenging conditions.“
Abomics collaborates with clinical laboratories to offer a pharmacogenetic test and interpretation report that helps doctors prescribe a medication and dosage based on the patient’s genetic characteristics. Abomics also produces medical and pharmaceutical databases, which support doctors in medication decisions.
Abomics acquired Multirec Oy in 2022. Multirec has over 20 years’ experience in delivering drug databases and drug related decision support to electronic patient records. Its good reputation and experience in collaboration with the leading electronic patient record vendors helps Abomics to create user-friendly integration of pharmacogenetics into clinical routines.
Mikko Välimäki has been appointed to Abomics’ Board of Directors, while Ari Hakkarainen has concluded his term. Välimäki brings extensive experience in technology companies, entrepreneurship, and international growth, strengthening the Board’s work in supporting the company’s long-term development.
Abomics has appointed a new Lead Bioinformatician to deepen its expertise in genomics and pharmacogenetics. The role strengthens scientific capabilities behind clinically actionable solutions and supports the practical implementation of precision medicine in healthcare settings.
Abomics has renewed its ISO 13485:2016 certification, confirming that its pharmacogenetic reporting and clinical decision support solutions meet internationally recognized quality standards. The certification reinforces consistent, risk-based processes that support safe and reliable implementation.